BLUS moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

BLUSF: effective Aug. 19,2019 a one for 3.6 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

BLUSF buy 2.07200

http://www.bellushealth.com/




normal chart









log chart









normal chart








log chart

where is the interest at?

Right on the 200ma huge support only morons would sell there imo ;)

Here we go baby, whoever wanted out is out already ;)

Buying ;

What happen today?

Hello ?? where is everyone?

Let's hope everyone who wanted out is now out.

Getting thumped today.

today announced the completion of the KIACTA™ (eprodisate) Phase 3 confirmatory study for the treatment of AA amyloidosis. Top-line results are expected to be announced in Q2 2016 after all remaining patients have completed final study visits, all queries have been resolved based on input from study sites and the database has been locked.
http://ih.advfn.com/p.php?pid=nmona&article=70080770

Great article !!

http://biotechnologyfocus.ca/big-things-brewing-at-bellus-could-an-exit-be-on-the-horizon/

I agree. I have a feeling they are under agreement because they have not mentioned anything after the Bloom Burton conference. If they do sell Kiacta for $1 billion…after the split its $10 for every share we own. I am thinking a special dividend payout ?

Where is everyone?........This is a 10 bagger in the making

What? You couldn't wait another day for me?

Where are we with this? Key here is Enrollment is expected to be completed in the second quarter of 2014. Could be March madness?

Most definitely fam401!

I'm guessing we will get a nice boost in PPS when enrollment is completed. If the CEO credentials are authentic I think this has great potential!

Key here is Enrollment is expected to be completed in the second quarter of 2014...

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=96549231

The Phase III Confirmatory Study is designed to confirm the safety and efficacy of KIACTATM, previously demonstrated in a Phase II/III study, in preventing kidney function decline in patients diagnosed with AA amyloidosis. AA amyloidosis is an orphan indication resulting in kidney dysfunction that often rapidly leads to dialysis and death.

The study is expected to enroll approximately 230 patients from more than 70 sites in 30 countries worldwide. To date, the study has enrolled approximately 200 patients. Enrollment is expected to be completed in the second quarter of 2014.

Product pipelines. ref. http://www.bellushealth.com/English/products/product-pipeline-overview/default.aspx

Do you expect a steady run up until then?

~ thank you Bio Specialist!

full phase 3 results will be out in 2016 but we can expect interim results later this year .

question to the board: when will their p3 data out? do you know? (i found this stock on yahoo finance) tia

Thank you for your opinion! Greatly appreciated!

From scrapped info out on the web. Bellus Health Inc. formerly known as "Neurochem" was worth $30 per Share in donkey years (2007)

It has a mixed results from an Alzheimer study and the stock never recovered but now the time has changed and it could see double digits again..

I have no future out look or targets for BELLUS but I plan on entry beginning of Feb. here. I would say "YES" to now is a good time to buy because I only look for stocks with potentials that are less than $5 IMO

http://investorshub.advfn.com/SmurfVAs-Random-Picks-27687/

What's your out look on 2014 for this company? Good time to buy?

Looking to get in on some BLUSF here for Feb.

What's the potential target on this one?

BLUSF-DD ..A FANTASTIC INVESTMENT TO MAKE BIG MONEY !!!


Just look at Volume and you will know that almost nobody knows this Monster Sleeping Giant with brutally upside potential means you have the opportunity to buy at the Bottom and before it hit the radar of investors .

Here is Why i like the Company so much :

1) Trading at Cash Level
2) Very Low Burn-Rate of $900k per Q (Cash untill Late 2017)
3) Strong Insider and Institutional Ownership (Holding 70% of the 47.3 M Share Outstanding )
4) KIACTA™ for AA Amyloidosis has Orphan Drug Status (NO approved Drugs for this Indication)
5) Previous Phase 3 of KIACTA™ was Successful and they just need the same results in the ongoing Phase 3 to get Approval
6) Great CEO who sold another Company for $4 B to Shire


Bellus Health (BLU.TO) (BLUSF)

Market Cap: $17.6 M
Cash: $16.3 M
Price: $0.41

Shares Outstanding: 47.4 M ( 70% of these Shares held by Insiders and Institutions)


New Slide Presentation ( Jan 2014)
http://www.bellushealth.com/files/doc_presentations/Bellus%20Corporate%20Presentation%20January%202014%20vFINAL.pdf


Interview with Ceo (November 2013)
http://watch.bnn.ca/#clip1047918


Interview
http://www.pharmaboardroom.com/article/interview-roberto-bellini-president-ceo-bellus-health-canada


BELLUS Health’s experienced clinical development team focuses on bringing compounds from the preclinical stage through clinical trials.

The Company’s lead program is KIACTA™, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death. KIACTA™ is partnered with global private equity firm Auven Therapeutics. KIACTA™ peak annual revenues are projected at $400-600 million (U.S., EU5, Japan).

In addition to KIACTA™, BELLUS Health’s pipeline includes Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli ("sHUS"). Shigamab™ has recently completed a Phase II clinical trial.
-
Some key reasons to consider investing in BELLUS Health include:

Focus on rare diseases – pipeline of rare disease projects in areas of high unmet medical need

Late stage pipeline – global Phase III study for KIACTA™ currently enrolling patients

Fully funded business plan – strong balance sheet with cash runway that will meet funding requirements beyond 2017

Key shareholders –shareholder base with proven track record of building successful healthcare companies

----------------------------------------------------
KIACTA™ peak annual revenues projected at $500 million (Summary)


Strong Clinical Results in First Phase III Study
Landmark study in AA amyloidosis: 183 patients treated for 2 years

Important benefits for patients on drug:

Statistically significant reduction in number and risk of reaching
worsening kidney event

Important delay in reaching dialysis New England Journal of
Medicine publication concludes that KIACTA TM slows decline of renal function in AA amyloidosis

MARKET SIZE

Orphan drug designation granted with market protection in the U.S. (7years), Europe and Japan (10 years)
Formulation (Dosing Schedule) and Methods for Treating Amyloidosis with expiry in 2026 5 year patent extension can be applied to provide protection until 2031

MARKET PROTECTION

KIACTA™ peak annual revenues projected at $500 million Clear pharmacoeconomic
rationale due to high cost of kidney disease Premium pricing for comparative rare disease drugs

PARTNERSHIP

Partnership to fund Phase III Confirmatory Study with significant upside for BELLUS shareholders
With global fund Auven Therapeutics, a private equity group specialized in drug development project
financing Auven Therapeutics funding 100% of KIACTA™’s Phase III Confirmatory Study

FINANCIALS

US$10M in upfront by Auven Therapeutics
US$50M in investments by Auven Therapeutics
Proceeds of exit expected to be shared 50-50

Yea it's looking good for 2011 IMO mod me up bro

You like AVOP?

hey add me as a mod on AVOP so I can work on the ibox, or let me take over the mod

add me as assistant mod on AVOP please

thanks

Volume stays like this and I may add some.

Blus + Volume = Plus

$207,000 in volume today.

Volume picking up.

Looks like there may be some life here. New clinical study started 12/14. Nice to NOT see a flat line stock price after so much time.

Sell Bellus Health Shares to $1
Wednesday May 7, 2:41 pm ET
By Jason Napodano, CFA

Bellus Health, Inc. (NasdaqGM: BLUS - News) is a biopharmaceutical company focused on the development and commercialization of products for the treatment of neurological disorders. The company currently has two candidates under various stages of clinical development.

However, late-stage pipeline setbacks have sent the companyâ€s shares plunging. In July 2007, the FDA issued a second 'approvable' letter for Kiacta, requesting an additional trial and additional pharmacokinetic data. This was followed by negative results from the North American phase III trial of the companyâ€s biggest potential product, Alzhemed.

The FDA indicated that an additional trial with a p-value of 0.05, along with further pharmacokinetic studies, will be required before the agency approves Kiacta. This was followed by negative results from the Alzhemed trial in August 2007. The share price plummeted over 40% on the news.

To add to Bellus†woes, the cash position is a matter of grave concern. With such late-stage pipeline setbacks, the company intends to fund operations for the remainder of 2008 with $43.4 million in cash.

The rest of the pipeline looks lackluster and does not hold much promise. Given the significant lack of positive catalysts, we rate the shares a Sell with a target price of $1.

Arpita Dutt, CA, contributed to this report.

BELLUS HEALTH reports results for first quarter of fiscal 2008
Monday May 5, 4:50 pm ET

LAVAL, QC, May 5 /PRNewswire-FirstCall/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU, formerly known as Neurochem Inc.) reported results for the first quarter ended March 31, 2008. The Company reported a net loss of $12,902,000 ($0.26 per share) for the quarter, compared to $21,016,000 ($0.54 per share) for the same period the previous year. The decrease in the net loss is mainly due to a reduction in research and development (R&D) expenses, before research tax credits and grants, which amounted to $8,780,000 this quarter, compared to $16,828,000 for the same period the previous year. The decrease in R&D expenses is mainly attributable to a reduction in expenses incurred in relation to the development of tramiprosate (ALZHEMED(TM); homotaurine) for the treatment of Alzheimer's disease, following the Company's decision in November 2007 to terminate the tramiprosate (ALZHEMED(TM)) pharmaceutical drug development program and to take steps to commercialize homotaurine (VIVIMIND(TM)) as a branded nutraceutical.

As at March 31, 2008, the Company had available cash, cash equivalents and marketable securities of $43,448,000, compared to $58,672,000 at December 31, 2007. BELLUS Health is expecting to further reduce its burn rate during fiscal 2008.

Consolidated Financial Results Highlights

The shareholders of Neurochem Inc. approved the change of its name to "BELLUS Health Inc." at the Annual and Special Shareholders' Meeting on April 15, 2008. The new stock ticker symbols, BLUS (NASDAQ) and BLU (TSX), came into use on April 21, 2008.

The Management's Discussion and Analysis (MD&A) provides a review of the Company's operations, performance and financial position for the quarter ended March 31, 2008, compared with the quarter ended March 31, 2007. It should be read in conjunction with the Company's unaudited consolidated financial statements for the three-month period ended March 31, 2008, as well as the Company's audited consolidated financial statements for the year ended December 31, 2007, which have been prepared in accordance with Canadian Generally Accepted Accounting Principles (GAAP). For discussion regarding related-party transactions, contractual obligations, disclosure controls and procedures, internal control over financial reporting, critical accounting policies and estimates, recent accounting pronouncements, and risks and uncertainties, refer to the Annual Report and the Annual Information Form for the year ended December 31, 2007, as well as registration statements and other public filings, which are available on SEDAR at www.sedar.com - or on EDGAR at www.sec.gov. This document contains forward-looking statements, which are qualified by reference to, and should be read together with the "Forward-Looking Statements" cautionary notice, which can be found at the end of this MD&A. This MD&A was prepared by management with information available as of May 5, 2008.

As previously reported, effective July 1, 2007, the Company adopted the US dollar as its functional and reporting currency, as a significant portion of its revenue, expenses, assets, liabilities and financing are denominated in US dollars. All currency figures reported in this document, including comparative figures, are reported in US dollars, unless otherwise specified.

Results of Operations
http://biz.yahoo.com/prnews/080505/mo416.html?.v=4

Neurochem to Change Name and Ticker; Stock Up

Neurochem Inc. (NRMX) shares were up more than 17% on Tuesday morning as shareholders settle in at the company's annual and special meeting in downtown Montreal where they will usher in a new era for the company.

Shareholders will be asked to officially adopt Neurochem's new name, BELLUS Health Inc., which it expects to start using on April 21, 2008, together with the new stock ticker symbols [TSX/BLU, BLUS/NASDAQ].

Neurochem will also present the launch activities that are in preparation for VIVIMIND [TM], the first branded natural health product to be marketed by its new, wholly-owned, nutraceutical subsidiary, OVOS Natural Health Inc., to protect memory function.

Shareholders will also learn that Neurochem has regained full ownership rights and control on eprodisate (KIACTA [TM]) from Centocor Inc., a wholly-owned subsidiairy of Johnson and Johnson (JNJ), for the prevention and treatment of Amyloid A [AA] amyloidosis.

http://seekingalpha.com/article/72464-neurochem-to-change-name-and-ticker-stock-up?source=yahoo

At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
Tuesday April 15, 7:00 am ET
Neurochem Annual and Special Meeting web cast live

LAVAL, QC, April 15 /PRNewswire-FirstCall/ - At the Annual and Special meeting of Neurochem Inc. (NASDAQ: NRMX - News; TSX: NRM - News), shareholders will be asked to officially adopt the Company's new name, BELLUS Health Inc., which it expects to start using on April 21, 2008, together with the new stock ticker symbols (NASDAQ: BLUS - News; TSX: BLU - News). Neurochem will also present the launch activities that are in preparation for VIVIMIND(TM), the first branded natural health product to be marketed by its new, wholly owned, nutraceutical subsidiary, OVOS Natural Health Inc., to protect memory function. Shareholders will also learn that Neurochem has regained full ownership rights and control on eprodisate (KIACTA(TM)) from Centocor Inc., a wholly owned subsidiairy of Johnson and Johnson, for the prevention and treatment of Amyloid A (AA) amyloidosis.

"Fiscal 2007 was a difficult year for Neurochem, but we have risen to the challenge by adopting an expanded corporate strategy to assure revenue generation in the short-term through the sale of natural health products and long-term development of a rich product pipeline in pharmaceuticals," said Dr. Francesco Bellini, Neurochem's Chairman, President and Chief Executive Officer. "Our name-change to BELLUS Health will reflect the broader scope of our activities, while the creation of our subsidiary, OVOS Natural Health, as well as the imminent launch of VIVIMIND(TM) for memory protection, testify to our determination to move ahead quickly. Our proactive strategy is based on the wealth of our past experience and the unique opportunity that the natural health product market represents to meet the needs of those who could benefit from this product, while helping to fund our longer-term drug development programs geared to future growth," he stated.

"I am particularly pleased to have regained full ownership of KIACTA(TM) given the promising results from our Phase II/III trial and our intention to initiate another Phase III trial and complete the development of this product candidate," Dr. Bellini concluded.

OVOS Natural Health - Launch activities in preparation for VIVIMIND(TM)

Fifteen years of combined scientific research including clinical trials with over 2,000 individuals in Canada, the United States and Europe and millions of dollars invested lie behind OVOS Natural Health's claim that VIVIMIND(TM) can help protect memory function and reduce age-associated brain volume loss normally leading to cognitive problems. The Company is looking to the natural health product market to make homotaurine, a naturally occurring ingredient otherwise found in algae available to the public given its good safety and tolerability profiles and the wealth of data supporting the impact on memory function and brain structures associated with memory and learning.

Following post-hoc analyses, the results in previous human testing clearly showed that homotaurine had a statistically significant dose-dependent effect and reduced by at least 68% (p-value 0.035) the loss of hippocampal volume over time in the individuals tested when compared to the untreated group. An almost statistically significant clinical benefit equivalent to 33% less decline (p-value: 0.065) on their cognitive tests as measured by ADAS-cog was also observed in individuals receiving homotaurine. The launch activities for VIVIMIND(TM) are in preparation.

"No other product on the natural health product market addressing memory function comes with the scientific background for safety and indications of effectiveness that VIVIMIND(TM) can claim," stated Mr. Gary Schmid, newly appointed President and Chief Executive Officer of OVOS Natural Health Inc. "VIVIMIND(TM) is in a class by itself and we plan to make it the leader in the fast growing baby boomer, or zoomer, market where a key concern is to maintain health and delay the effects of aging," he added.

VIVIMIND(TM) will be made available to consumers through traditional retail channels, such as drug stores, mass merchandisers and grocery chains, as well as through leading health food stores. OVOS Natural Health is working towards the launch of a major advertising and information campaign for consumers.

New Pharmaceutical Development Pipeline

As previously announced, Neurochem will initiate a second Phase III clinical trial for eprodisate (KIACTA(TM)) in close cooperation with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). This investigational product candidate is being developed for the treatment of a rare but devastating disease, Amyloid A (AA) amyloidosis, which attacks the kidney function and often leads to death.

The trial is expected to begin in the fourth quarter of 2008. It will be an international, double-blind, randomized, placebo-controlled and parallel design study of approximately 150 patients to be followed for a period of 24 months.

NC-503 is being studied for the treatment of Type II diabetes and certain features of metabolic syndrome. Results from animal studies using a rat model of diabetes and metabolic syndrome have shown that NC-503 protects the kidney and decreases the glycemic levels in obese diabetic, so-called Zucker rats, when compared to the control group. Treatment with NC-503 correlated with the preservation of 40% more cells secreting insulin than in the control group.

This program has now advanced into a Phase II clinical trial in diabetic patients in Canada. The study is a 26-week, double-blind, placebo-controlled, randomized study. Interim results are expected in late 2008 or early 2009. The screening of the first patient for this study was completed last week.

Leveraging the many years of accumulated knowledge and the experience it has gained in developing tramiprosate (ALZHEMED(TM)) for the treatment of Alzheimer's disease (AD), Neurochem will prioritize and accelerate the development of a prodrug of tramiprosate (ALZHEMED(TM)), a new chemical entity (NCE), for the treatment of AD. A prodrug is a pharmaceutical substance which is administered in an inactive form and, once absorbed, is metabolized in vivo into its active form (in this case, tramiprosate). This NCE has potential patent protection until 2027.

Financial Update

Neurochem indicated that it expects to spend less in fiscal 2008 than in 2007, due in large part to the discontinuation of the European Phase III clinical trial for tramiprosate (ALZHEMED(TM)). The Company completed fiscal 2007 with approximately US$59 million cash on hand, enough to finance the current needs of Neurochem's pharmaceutical and branded nutraceutical activities. Management indicated that additional financing could be contemplated if required and that it can count on the continued support of Picchio Pharma, the Company's major shareholder

Following the Drugmaker Formerly Known as Neurochem:

http://www.fool.com/investing/high-growth/2008/04/02/following-the-drugmaker-formerly-known-as-neuroche.aspx

Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
Thursday March 13, 7:00 am ET

ECUBLENS, SWITZERLAND, March 13 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX - News; TSX: NRM - News), announces that the Company is taking new initiatives to pursue the drug development program for its investigational product candidate, eprodisate (KIACTA(TM)), to obtain market approval for the treatment of Amyloid A (AA) amyloidosis. Neurochem's decision to build upon its eprodisate (KIACTA(TM)) asset and take steps to initiate a second Phase III clinical trial is based principally on the fact that AA amyloidosis is a life-threatening disease for which there is no specific treatment, on the data obtained from the first Phase II/III clinical trial, which yielded promising efficacy results on the study endpoints, on the benign safety profile of eprodisate (KIACTA(TM)) in patients diagnosed with AA amyloidosis, and on its discussions with the regulatory agencies and related scientific advisory committees. As part of the approval process for the investigational product candidate, both the regulatory agencies in the United States and in the European Union recommended an additional confirmatory efficacy Phase III clinical trial, which will have a target significance level (p-value) of 0.05 rather than the p-value of 0.01, which had been required for an approval based on a single efficacy study. Based on these recommendations, the Company will enter into discussions with the U.S. Food and Drug Administration (FDA) and with the European Medicines Agency (EMEA) to reach agreement on the terms for an approval of eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis. As part of this strategic decision, the Company is also announcing that it is withdrawing its current marketing applications for eprodisate (KIACTA(TM)) in the United States, the European Union and Switzerland.

Bought back into NRMX, too many shorts still in this "bow wow"

Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
Wednesday February 20, 7:12 pm ET
Neurochem will host a conference call Thursday, February 21, 2008, at 8:30 A.M. ET.

LAVAL, QC, Feb. 20 /PRNewswire-FirstCall/ - Neurochem Inc. (NASDAQ: NRMX - News; TSX: NRM - News) reports results for the fourth quarter and fiscal year ended December 31, 2007, and announces important advances regarding the Company's pharmaceutical and nutraceutical activities. The Company reports, for the fourth quarter, a net loss of $16,097,000 ($0.33 per share), compared to $17,011,000 ($0.44 per share) for the corresponding period in the previous year. For the year ended December 31, 2007, the net loss amounted to $81,486,000 ($1.85 per share), compared to $66,469,000 ($1.72 per share) for the same period last year. The net loss for the year ended December 31, 2007, includes a non-recurring charge in the second quarter of fiscal 2007 under Canadian GAAP of $10,430,000 relating to the $40 million 5% senior subordinated convertible notes, which were fully converted into common shares during the second quarter of 2007. In total, accretion expense amounted to $15,751,000 for the year ended December 31, 2007. As at December 31, 2007, the Company had available cash, cash equivalents and marketable securities of $58,672,000, compared to $48,758,000 at December 31, 2006. All figures are in U.S. dollars, unless otherwise specified.

Furthermore, the Company is pleased to announce the following important developments:

- The regulatory submission for the initiation of the Phase II clinical
trial with the investigational product candidate NC-503 in patients
with Type II Diabetes as well as certain features of Metabolic Syndrome
was accepted by the Therapeutic Products Directorate of Health Canada.
As a result, the first patient is expected to be enrolled shortly. The
key objectives of the study are to investigate the safety and proof-
of-concept efficacy of NC-503 on glycemic measures.
- In order to more accurately reflect the Company's expanded business
strategy and core programs that encompass both therapeutics and branded
nutraceutical products, and following the approval by Neurochem's Board
of Directors, the name-change from Neurochem to BELLUS HEALTH(TM),
pending shareholder approval at the next annual meeting.
- Approval by Neurochem's Board of Directors for the creation of
subsidiaries for the purposes of carrying on the Company's
nutraceutical business, and as part of these new developments, the
nutraceutical business will be named OVOS NATURAL HEALTH(TM).
- An amendment under the Equity Line of Credit Facility, extending the
term to February 2010. The minimum draw-down obligation by the Company
has been reduced to $15,000,000 over the term. The maximum amount of
each monthly draw-down is limited to the lower of $6,000,000 or
12.5% of the volume-weighted price calculation of the common shares at
the time of draw-down. The common shares will be issued at a discount
of 4.0% to market price if the volume-weighted average price (VWAP)
per share is $6 or higher and 7% if the VWAP per share is lower than $6
at the time of draw-down.

"Neurochem is making significant progress in the implementation of the strategy that aims to make homotaurine available to consumers. Our drive towards the commercialization of this brand under the leadership of Mr. Gary Schmid as CEO of our nutraceutical business is geared towards potentially selling homotaurine via the Internet as early as the second quarter of 2008 and made available at retail in Canada during the third quarter of 2008," said Dr. Francesco Bellini, Chairman, President and CEO of Neurochem. "With respect to our pharmaceutical activities, we are continuing to accelerate the development of our product candidates in the field of Diabetes and Alzheimer's disease and closely working with the regulatory agencies in Europe and the United States to hopefully be in a position to make KIACTA(TM) available to patients suffering from Amyloid A (AA) amyloidosis. The launch of a Phase II study for NC-503 as a treatment for Type II Diabetes as well as certain features of Metabolic Syndrome is very encouraging. As a natural extension of our work in the field of AA amyloidosis, we start with a solid base of knowledge and research already completed," Dr. Bellini concluded.

http://biz.yahoo.com/prnews/080220/mo322.html?.v=1

Ticking higher again.